Quick Answer
Ensysce Biosciences, Inc. reported Diluted EPS of $3.98 per share (loss) for fiscal year 2025.
Ensysce Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.98 | +65.2% |
| 2024 | -$11.45 | +83.7% |
| 2023 | -$70.40 | +49.5% |
| 2022 | -$139.42 | -9320.3% |
| 2021 | -$1.48 | — |
| 2020 | $0.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.29 | -229.0% | -63.3% |
| June 30, 2025 | -$0.79 | +76.4% | +43.2% |
| March 31, 2025 | -$1.39 | +83.1% | -239.0% |
| September 30, 2024 | $1.00 | +214.9% | +129.9% |
| June 30, 2024 | -$3.35 | -241.8% | +59.2% |
| March 31, 2024 | -$8.21 | -294.7% | -843.7% |
| September 30, 2023 | -$0.87 | +98.6% | +11.2% |
| June 30, 2023 | -$0.98 | +98.3% | +52.9% |
- Ensysce Biosciences, Inc. showed an increase of +65.2% in Diluted EPS compared to the prior fiscal year.
- The most recent figure is from Ensysce Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: